Graduate Program of Industrial Pharmaceutical Science, Yonsei University, Incheon, Republic of Korea.
College of Pharmacy, Dankook University, Cheonan, Republic of Korea.
Front Neuroendocrinol. 2024 Apr;73:101131. doi: 10.1016/j.yfrne.2024.101131. Epub 2024 Feb 16.
This systematic review and meta-analysis aimed to determine the association between the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors and dementia onset as well as cognitive function in patients with diabetes mellitus. We comprehensively searched the MEDLINE, Embase, and CENTRAL databases to select relevant studies published up to August 2023. The use of SGLT-2 inhibitors significantly lowers dementia risk compared to SGLT-2i non-users (Hazard ratio: 0.68, 95 % CI: 0.50-0.92). Furthermore, our findings indicated a positive effect of SGLT-2 inhibitor use on cognitive function score improvement, as demonstrated by the standardized mean difference of 0.88 (95 % CI: 0.32-1.44), particularly among populations with mild cognitive impairment or dementia. This systematic review and meta-analysis indicate a potential role of SGLT-2 inhibitors in reducing the risk of dementia in patients with diabetes mellitus. These findings underscore the need for well-controlled large clinical trials and future research in this field.
这篇系统评价和荟萃分析旨在确定钠-葡萄糖共转运蛋白 2 (SGLT-2) 抑制剂的使用与糖尿病患者痴呆发病和认知功能之间的关系。我们全面检索了 MEDLINE、Embase 和 CENTRAL 数据库，以选择截至 2023 年 8 月发表的相关研究。与 SGLT-2i 非使用者相比，使用 SGLT-2 抑制剂显著降低痴呆风险（风险比：0.68，95%置信区间：0.50-0.92）。此外，我们的研究结果表明，SGLT-2 抑制剂的使用对认知功能评分的改善有积极影响，标准化均数差为 0.88（95%置信区间：0.32-1.44），尤其是在轻度认知障碍或痴呆的人群中。这项系统评价和荟萃分析表明，SGLT-2 抑制剂在降低糖尿病患者痴呆风险方面可能具有作用。这些发现强调了在该领域进行精心控制的大型临床试验和未来研究的必要性。
